In the last trading session, 7.33 million Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares changed hands as the company’s beta touched 0.28. With the company’s per share price at $0.37 changed hands at -$0.24 or -38.84% during last session, the market valuation stood at $8.24M. CYCC’s last price was a discount, traded about -10667.57% off its 52-week high of $39.84. The share price had its 52-week low at $0.58, which suggests the last value was -56.76% down since then.
Analysts gave the Cyclacel Pharmaceuticals Inc (CYCC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CYCC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Instantly CYCC was in red as seen at the end of in last trading. With action -77.30%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -93.85%, with the 5-day performance at -77.30% in the red. However, in the 30-day time frame, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is -92.73% down.
The consensus price target for the stock as assigned by Wall Street analysts is 1, meaning bulls need an upside of 63.0% from its current market value. According to analyst projections, CYCC’s forecast low is 1 with 1 as the target high. To hit the forecast high, the stock’s price needs a -170.27% plunge from its current level, while the stock would need to soar -170.27% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 57.31%.
CYCC Dividends
Cyclacel Pharmaceuticals Inc is expected to release its next quarterly earnings report in July. The 648.65% annual yield figure for the share gives it an annual dividend of 2.40. It is important to note, however, that the 648.65% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.
Among Mutual Funds, the top two as of Mar 31, 2025 were Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund . With 3.24 shares estimated at $1198.0 under it, the former controlled 0.01% of total outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund held about 0.00% of the shares, roughly 653.0 shares worth around $241.0.
